BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 10,589 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 10,589 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $239,946.74. Following the completion of the transaction, the executive vice president now owns 309,576 shares of the company’s stock, valued at $7,014,992.16. The trade was a 3.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

BioLife Solutions Stock Down 5.6 %

Shares of BLFS stock traded down $1.34 during midday trading on Thursday, reaching $22.44. 591,144 shares of the stock were exchanged, compared to its average volume of 358,590. BioLife Solutions, Inc. has a 1 year low of $14.84 and a 1 year high of $29.55. The firm has a market cap of $1.05 billion, a PE ratio of -21.17 and a beta of 2.04. The company’s 50 day moving average is $26.11 and its two-hundred day moving average is $25.54. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The company had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same period last year, the business earned ($0.21) EPS. On average, equities research analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Northland Securities boosted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. KeyCorp boosted their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. HC Wainwright lifted their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Benchmark restated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, StockNews.com lowered shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Monday. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to data from MarketBeat, BioLife Solutions presently has an average rating of “Moderate Buy” and an average target price of $29.86.

Institutional Investors Weigh In On BioLife Solutions

Several institutional investors have recently modified their holdings of BLFS. Intech Investment Management LLC purchased a new position in BioLife Solutions during the third quarter valued at approximately $255,000. Charles Schwab Investment Management Inc. increased its position in BioLife Solutions by 3.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 319,959 shares of the medical equipment provider’s stock valued at $8,012,000 after acquiring an additional 9,750 shares during the last quarter. Cerity Partners LLC lifted its stake in BioLife Solutions by 6.6% in the third quarter. Cerity Partners LLC now owns 44,914 shares of the medical equipment provider’s stock worth $1,125,000 after purchasing an additional 2,776 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in BioLife Solutions by 40.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock valued at $487,000 after acquiring an additional 5,638 shares during the period. Finally, FMR LLC grew its holdings in shares of BioLife Solutions by 470.6% in the third quarter. FMR LLC now owns 13,317 shares of the medical equipment provider’s stock worth $333,000 after purchasing an additional 10,983 shares during the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.